Design Therapeutics, Inc. announced that Jae Kim, M.D., FACC, has been appointed as chief medical officer. Dr. Kim will play a pivotal role in leading clinical strategy and development, including the company's first clinical trial planned to begin in the first half of 2022. Dr. Kim joins Design from Avidity Biosciences, where he served as chief medical officer until August 2021 and led the advancement of the company's pipeline, including the initiation of the company's first-in-human study, a Phase 1/2 clinical trial in patients with myotonic dystrophy type-1.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.05 USD | +2.79% | -7.11% | +52.83% |
05-08 | Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-07 | Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.83% | 223M | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- DSGN Stock
- News Design Therapeutics, Inc.
- Design Therapeutics, Inc. Appoints Jae Kim, M.D., as Chief Medical Officer